Reduced bone mineral density in HIV-positive individuals

AL Moore, A Vashisht, CA Sabin, A Mocroft, S Madge… - Aids, 2001 - journals.lww.com
AL Moore, A Vashisht, CA Sabin, A Mocroft, S Madge, AN Phillips, JWW Studd, MA Johnson
Aids, 2001journals.lww.com
A total of 105 HIV-positive patients underwent dual-energy X-ray absorbtiometry (DEXA)
scan to assess bone mineral density (BMD). The prevalence of reduced BMD was found to
be 71% and was higher in patients who had ever been treated with protease inhibitors (PI).
Our results suggest a possible association between PI and reduced BMD, and further
complicate the debate regarding when to commence treatment of HIV and with what agents
to start.Highly active antiretroviral therapy has radically improved the prognosis of patients …
A total of 105 HIV-positive patients underwent dual-energy X-ray absorbtiometry (DEXA) scan to assess bone mineral density (BMD). The prevalence of reduced BMD was found to be 71% and was higher in patients who had ever been treated with protease inhibitors (PI). Our results suggest a possible association between PI and reduced BMD, and further complicate the debate regarding when to commence treatment of HIV and with what agents to start.
Highly active antiretroviral therapy has radically improved the prognosis of patients infected with HIV [1, 2]. Metabolic complications related both to living with HIV long term and the use of antiretroviral treatment have increasingly been noted [3, 4], and several groups have reported reduced bone mineral density (BMD) in HIV infection [5–8], some suggesting an association with protease inhibitors (PI)[7]. Dual-energy X-ray absorbtiometry (DEXA) scan is used to determine BMD, and results may be categorized by T score (which compares an individual's BMD with the mean peak bone density for that sex in the general population, the WHO defining osteopenia as a T score of between 1 and 2.5 SD below the mean and osteoporosis as a T score of> 2.5 SD below the mean)[9]. Our study aimed to establish the prevalence of reduced BMD in a single clinic population of HIV-positive individuals, and to identify factors associated with this abnormality.
Lippincott Williams & Wilkins